2篇
您的检索式：作者名="Yeling Ruan"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Synthesis of porphyrin sensitized TiO2/graphene and its photocatalytic property under visible light显示文摘 | RUAN C H ZHANG L F YELING Q L | 2015 | Materials Letters2015，141，： | 1 |
| 2 | UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGCip in hepatocellular carcinoma显示文摘The treatment for hepatocellular carcinoma(HCC)is promising in recent years,but still facing critical challenges.The first targeted therapy,sorafenib,prolonged the overall survival by months.However,resistance often occurs,largely limits its efficacy.Sorafenib was found to target the electron transport chain complexes,which results in the generation of reactive oxygen species(ROS).To maintain sorafenib resistance and further facilitate tumor progression,cancer cells develop strategies to overcome excessive ROS production and obtain resistance to oxidative stress-induced cell death.In the present study,we investigated the roles of ROS in sorafenib resistance,and found suppressed ROS levels and reductive redox states in sorafenib-resistant HCC cells.Mitochondria in sorafenib-resistant cells maintained greater functional and morphological integrity under the treatment of sorafenib.However,cellular oxygen consumption rate and mitochondria DNA content analyses revealed fewer numbers of mitochondria in sorafenib-resistant cells.Further investigation attributed this finding to decreased mitochondrial biogenesis,likely caused by the accelerated degradation of peroxisome proliferator-activated receptor y coactivator ip(PGC1P).Mechanistic dissection showed that upregulated UBQLN1 induced PGCip degradation in a ubiquitination-independent manner to attenuate mitochondrial biogenesis and ROS production in sorafenib-resistant cells under sorafenib treatment.Furthermore,clinical investigations further indicated that the patients with higher UBQLN1 levels experienced worse recurrence-free survival.In conclusion,we propose a novel mechanism involving mitochondrial biogenesis and ROS homeostasis in sorafenib resistance,which may offer new therapeutic targets and strategies for HCC patients. | Junjie Xu Lin Ji Yeling Ruan Zhe Wan Zhongjie Lin Shunjie Xia Liye Tao Junhao Zheng Liuxin Cai Yifan Wang Xiao Liang Xiujun Cai | 2021 | Signal Transduction and Targeted Therapy2021，6，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员